Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 1073

1.

Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder.

Potkin SG, Saha AR, Kujawa MJ, Carson WH, Ali M, Stock E, Stringfellow J, Ingenito G, Marder SR.

Arch Gen Psychiatry. 2003 Jul;60(7):681-90.

PMID:
12860772
2.

Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder.

Kane JM, Carson WH, Saha AR, McQuade RD, Ingenito GG, Zimbroff DL, Ali MW.

J Clin Psychiatry. 2002 Sep;63(9):763-71.

PMID:
12363115
3.

The acute efficacy of aripiprazole across the symptom spectrum of schizophrenia: a pooled post hoc analysis from 5 short-term studies.

Janicak PG, Glick ID, Marder SR, Crandall DT, McQuade RD, Marcus RN, Eudicone JM, Assunção-Talbott S.

J Clin Psychiatry. 2009 Jan;70(1):25-35. Epub 2008 Dec 2.

PMID:
19192472
4.
5.

The efficacy, safety, and tolerability of aripiprazole for the treatment of schizoaffective disorder: results from a pooled analysis of a sub-population of subjects from two randomized, double-blind, placebo-controlled, pivotal trials.

Glick ID, Mankoski R, Eudicone JM, Marcus RN, Tran QV, Assunção-Talbott S.

J Affect Disord. 2009 May;115(1-2):18-26. doi: 10.1016/j.jad.2008.12.017. Epub 2009 Feb 23.

PMID:
19230981
6.

Efficacy and safety of aripiprazole in the acute treatment of schizophrenia in Chinese patients with risperidone as an active control: a randomized trial.

Chan HY, Lin WW, Lin SK, Hwang TJ, Su TP, Chiang SC, Hwu HG.

J Clin Psychiatry. 2007 Jan;68(1):29-36.

PMID:
17284127
7.

A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy.

Kane JM, Correll CU, Goff DC, Kirkpatrick B, Marder SR, Vester-Blokland E, Sun W, Carson WH, Pikalov A, Assunção-Talbott S.

J Clin Psychiatry. 2009 Oct;70(10):1348-57. doi: 10.4088/JCP.09m05154yel.

PMID:
19906340
8.

Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder.

Swainston Harrison T, Perry CM.

Drugs. 2004;64(15):1715-36. Review.

PMID:
15257633
9.

Long-term efficacy and safety of aripiprazole in patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder: 26-week prospective study.

Kwon JS, Jang JH, Kang DH, Yoo SY, Kim YK, Cho SJ; APLUS study group.

Psychiatry Clin Neurosci. 2009 Feb;63(1):73-81. doi: 10.1111/j.1440-1819.2008.01907.x.

10.

Efficacy and safety of aripiprazole in Chinese Han schizophrenia subjects: a randomized, double-blind, active parallel-controlled, multicenter clinical trial.

Li H, Luo J, Wang C, Xie S, Xu X, Wang X, Yu W, Gu N, Kane JM.

Schizophr Res. 2014 Aug;157(1-3):112-9. doi: 10.1016/j.schres.2014.05.040. Epub 2014 Jul 1. Erratum in: Schizophr Res. 2014 Oct;159(1):256.

PMID:
24994555
11.

Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study.

Pigott TA, Carson WH, Saha AR, Torbeyns AF, Stock EG, Ingenito GG; Aripiprazole Study Group.

J Clin Psychiatry. 2003 Sep;64(9):1048-56.

PMID:
14628980
12.

A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia.

Findling RL, Robb A, Nyilas M, Forbes RA, Jin N, Ivanova S, Marcus R, McQuade RD, Iwamoto T, Carson WH.

Am J Psychiatry. 2008 Nov;165(11):1432-41. doi: 10.1176/appi.ajp.2008.07061035. Epub 2008 Sep 2.

PMID:
18765484
13.
14.

Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.

Citrome L, Meng X, Hochfeld M, Stahl SM.

Hum Psychopharmacol. 2012 Jan;27(1):24-32. doi: 10.1002/hup.1254. Epub 2011 Dec 7.

PMID:
22161738
15.

Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials.

Marder SR, McQuade RD, Stock E, Kaplita S, Marcus R, Safferman AZ, Saha A, Ali M, Iwamoto T.

Schizophr Res. 2003 Jun 1;61(2-3):123-36.

PMID:
12729864
16.

Efficacy and safety of risperidone in the treatment of schizoaffective disorder: initial results from a large, multicenter surveillance study. Group for the Study of Risperidone in Affective Disorders (GSRAD).

Vieta E, Herraiz M, Fernández A, Gastó C, Benabarre A, Colom F, Martínez-Arán A, Reinares M.

J Clin Psychiatry. 2001 Aug;62(8):623-30.

PMID:
11561935
17.

A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety.

Anil Yağcioğlu AE, Kivircik Akdede BB, Turgut TI, Tümüklü M, Yazici MK, Alptekin K, Ertuğrul A, Jayathilake K, Göğüş A, Tunca Z, Meltzer HY.

J Clin Psychiatry. 2005 Jan;66(1):63-72.

PMID:
15669890
18.

Efficacy and safety of bifeprunox in patients with an acute exacerbation of schizophrenia: results from a randomized, double-blind, placebo-controlled, multicenter, dose-finding study.

Casey DE, Sands EE, Heisterberg J, Yang HM.

Psychopharmacology (Berl). 2008 Oct;200(3):317-31. doi: 10.1007/s00213-008-1207-7. Epub 2008 Jul 4.

PMID:
18597078
19.

Aripiprazole in schizophrenia and schizoaffective disorder: A review.

Stip E, Tourjman V.

Clin Ther. 2010;32 Suppl 1:S3-20. doi: 10.1016/j.clinthera.2010.01.021. Review.

PMID:
20152550
20.

Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with intramuscular haloperidol.

Andrezina R, Josiassen RC, Marcus RN, Oren DA, Manos G, Stock E, Carson WH, Iwamoto T.

Psychopharmacology (Berl). 2006 Oct;188(3):281-92. Epub 2006 Sep 5.

PMID:
16953381

Supplemental Content

Support Center